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Abstract 
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The topic of “Health Claims Substantiation for Probiotic and Prebiotic Products” was discussed at the 8
th
 
annual International Scientific Association for Probiotics and Prebiotics (ISAPP) meeting. The topic is 
especially timely considering that the regulatory review process for health benefit claims on probiotic and 
prebiotic products in Europe has not resulted in a single claim being approved (120 negative opinions on 
probiotic claims and 19 negative opinions on prebiotic claims through February 2011). This situation in 
Europe and elsewhere has driven companies to seek clarity on a research path that would stand up to 
scientific scrutiny as well as satisfy regulatory demands for health claim substantiation. It can be 
challenging to negotiate rigid regulatory distinctions, such as between health and disease, when these 
states are more realistically represented by continua. One research approach focused on improved 
homeostasis is explored as a statistically robust approach to measuring physiological parameters in 
healthy populations, which are the required target for food and supplement claims. Diverse global 
regulatory frameworks complicate this issue, and harmonization of different approaches globally would 
simplify requirements for industry, decrease consumer confusion and improve the scientific framework 
for the research community to set up appropriate research pathways. This report highlights key points 
from this discussion.  
 
Introduction 
In August, 2010, a discussion group on the topic of “Health Claims Substantiation for Probiotic and 
Prebiotic Products” was convened at the 8
th
 annual International Scientific Association for Probiotics and 
Prebiotics (ISAPP) meeting held just outside of Barcelona, Spain. The scope of this discussion was on 
regulatory issues with regard to substantiation of health claims on foods and food supplements (not 
drugs). The group was composed of academic and industry scientists, as well as lawyers specializing in 
food labeling (Table1). Although the discussion outline was comprehensive (Table 2), this report focuses 
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on the most important themes that emerged during the discussion. All these would be worthy of further 
consideration and consensus development. 
 
Regulatory boxes vs. continua 
 
Key differences between the current regulatory situations in Europe, the United States, Canada, Japan, 
China and India were discussed. An overriding challenge is managing the different ways that consumers, 
healthcare professionals, regulators, legislators and scientists see the health benefit claims on probiotic 
and prebiotic products. A lack of unified perspective exists: while most consumers, healthcare 
professionals and scientists perceive a continuum between the extremes of “health and disease”, ”food 
and drugs”, “emerging evidence and supported with significant scientific agreement ”, generally 
legislation – and the subsequent enforcement of this legislation – partitions these entities into distinct 
compartments (Figure 1). The regulatory box paradigm adopted by many countries imposes substantial 
hurdles for research, consumer understanding and marketing of functional foods. A scientific argument 
can be made that in the cases where a product meets the safety standard for a food, it would be sensible 
that labels on foods should be able to communicate whatever use is substantiated (accompanied, 
perhaps, by an indication of the strength of the support). However, in some regulatory frameworks, 
substances recognized in general as foods, which are safely consumed by consumers with suboptimal 
health status, are lumped together with drugs if they are labeled (or in some cases, even studied) to 
provide dietary management of health conditions, reduce the risk of developing an acute condition, 
ameliorate symptoms or improve a patient’s responsiveness to drug therapy. This conversion of foods into 
drugs occurs despite the fact that healthcare providers on a daily basis counsel their patients in how to 
incorporate foods into their diet for many of these supposed “treatment” purposes.  
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In many countries, the distinction between drugs and foods relies on how the product is labelled and 
used. A product labelled to treat or prevent disease is considered a drug by many regulatory frameworks, 
whereas foods may be used to support or maintain normal body functions or reduce the risk of disease in 
the generally healthy population. However, the distinction between disease prevention and risk reduction 
is not clear scientifically. Furthermore, the growing body of scientific evidence demonstrates that some 
foods may be able to prevent or mitigate certain disease or illness. Rigorous scientific demonstration of 
this capability may be rendered meaningless by regulatory constraints on communicating these findings. 
Also, even if the regulatory environment is restrictive of claims, it is important that it be recognized that 
there is a difference between research and claims, and even if allowable claims are limited, the research 
on foods shouldn’t be. The current interpretations of the border between foods and drugs perhaps made 
sense when less information was available about the role of food and food ingredients in maintaining 
health and affecting the structure and function of the body, and fewer borderline products existed. 
However, both the science and the markets have progressed. If regulations were written de novo today, 
functional foods and medicines might be regulated under a common framework for various types of 
health-related claims and their substantiation. A complicating situation is that despite the regulatory 
categories, the difference between food and drugs is not always clear to the consumer. 
 
There appears to be a similarly non-fluid regulatory view of health and disease in many countries.
1-4
 A 
noteworthy exception exists in Japan, where Foods for Specialized Health Use (FOSHU) is targeted not 
only to healthy people, but also to people at first stage of any illness or borderline conditions.
5
 Even 
though the medical community does not uniformly agree, people who may be experiencing suboptimal 
health, symptoms, syndromes or illness [defined as the subjective response of the patient to being 
unwell
6,7
] are all viewed as having a “disease” by many regulatory interpretations. Under this 
interpretation, use of a “food” to help improve such health conditions would be viewed as a drug-use and 
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would not be allowed. This is true even though in some cases, products commonly understood as foods 
may provide a safe and effective approach for the management of so-defined disease situations. For 
example, a food or dietary supplement shown to ameliorate the nausea that results from chemotherapy 
and thus help cancer patients reduce the inanition and wasting (but not treat the cancer) that often 
accompany the disease, should not be treated as a drug. Children with ear infections (but with healthy 
guts) prescribed antibiotics should be able to eat a probiotic- or prebiotic-containing food demonstrated 
by rigorous research to help keep their guts healthy during therapy. Certain probiotics have been shown 
to reduce the infection rate with Clostridium difficile,
8
 reduce the risk, severity, or duration of rotavirus-
induced gastroenteritis,
9 
reduce the risk of developing atopic dermatitis,
10, 11 
or reduce the incidence of 
common infectious diseases.
12, 13 
 Certain prebiotics have been shown to reduce the incidence of 
conditions such as travelers’ diarrhea,
14
 antibiotic-associated diarrhea
15 
and infant diarrhea.
16
  Examples of 
such uses for foods are numerous. Although the number of studies required to constitute convincing 
evidence for these uses is a subject of much discussion, the important point is that if validated, such uses 
for foods would be useful for consumers but often precluded by regulatory authorities. 
 
Another example where continua pose challenges for regulators lies in considering levels of evidence 
supporting health benefit claims. The strength of evidence on health benefits of foods can range from 
“emerging evidence” to “significant scientific agreement,” and understandably, regulations favor the 
latter over the former. In the European Union, whereas the review process is required to provide 
“scientific assessment of the highest possible standard,” health claims are “based on and substantiated by 
generally accepted scientific evidence.”
17
 However, it seems that in practice, the reviewers expect the 
evidence must meet the highest possible standard. In the United States the standard was “significant 
scientific agreement” until the Food and Drug Administration (FDA) was successfully sued on the basis that 
this standard unduly restricted commercial free speech.
18
 This ruling created “qualified health claims” in 
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the US, a standard which acknowledges the continuum between emerging evidence and significant 
scientific agreement. Although claims now can be based on evidence that falls short of significant scientific 
agreement, the claim still requires pre-approval from the FDA. Such qualified health claims pose the 
challenge of accurately communicating the subtleties of limited scientific evidence to scientifically naïve 
consumers. This is no trivial undertaking, and those tasked with approval of claim language clearly have an 
underlying concern for protecting the consumer against misleading marketing messages. Although the 
scientific community would agree that evidence in support of health claims must be compelling, it also 
recognizes that all studies have limitations, and a standard that requires a reasonable level of evidence of 
substantiation of a health benefit may serve all stakeholders better than a standard of the highest possible 
evidence. Finally, when considering the different standards of evidence required in different geographical 
regions, it becomes apparent that a harmonized approach to health benefit claims could provide clear 
benefits. Compliance with all regulations on substantiation and wording of health benefit claims in 
different regions of the world is a sizable challenge, and efforts to seek harmonization perhaps through 
Codex or other international collaborations could be worthwhile. 
 
Foods vs. drugs 
 
Certain current regulatory frameworks require that food-form products that prevent or manage diseases 
be subjected to drug oversight. But important differences exist between scientific substantiation for foods 
and drugs, and these differences can make it difficult (and unnecessary) for foods to meet drug 
standards.
19 
Some of these differences that are relevant to food as a subject of interventional human 
studies are:  
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• Foods and food ingredients meet a higher standard of safety than do drugs: risk vs. benefit is generally 
not part of the assessment. History of safe use is often an important component of safety 
assessments. 
• Foods are readily available to the total population, in non-limited amounts. Zero intake for a control 
group in a study may not be attainable. 
• Foods must be considered as part of an overall healthy diet. 
• Choice of a control product can be difficult when assessing functional ingredients in foods. The food 
without the functional ingredient is a likely choice for a control, but the control food itself may 
contribute to a physiological effect (e.g., conventional yogurt compared to a probiotic yogurt). The 
choice of a control product is driven in part by the research question being asked; however, to achieve 
blinding in a study on functional food, a control comprised of the food matrix must be used.  
• Generally the anticipated magnitude of effect is smaller than for drugs. 
• Unlike pills, food formulations can change frequently (new flavors, functional ingredients, levels of 
macronutrients, targeted formulations for different geographical regions). An important consideration 
for research on foods is determining when a new food formulation differs substantively from the 
researched food, requiring confirmatory efficacy studies. 
• Profit margins are lower for foods than for drugs. This leads to a disparity with research investment 
possible by food compared to drug companies  
• Foods are most often natural rather than synthetic products, not produced under drug manufacturing 
practices, and are more likely to show batch-to-batch variability.  
 
It should be noted that although dietary supplements are generally considered within food regulations, 
some of the differences highlighted above between foods and drugs do not pertain to dietary 
supplements. For example, formulation of an inert placebo for a dietary supplement is generally a 
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straightforward choice, supplements do not contribute calorically to consumers’ diet, matrix effects may 
not be as variable for supplement formulations and zero-intake may be easy to establish for subjects in 
studies.  
 
Studies on foods should be of high-quality and well-controlled. But differences between foods and drugs 
compel recognition that the type of evidence required for efficacy may be different. For example, 
Blumberg et al.
20
 recently questioned the appropriateness of randomized controlled trials for foods. 
 
A regulatory framework that recognized the existence of the above-described continua would provide an 
environment where the full role of foods (including nutritional supplements) in promoting health, 
reducing the risk of disease and managing health conditions could be realized.  
 
Implementing such a regulatory framework would present numerous challenges, but in the end 
consumers may benefit from such changes. However, one unintended consequence of this regulatory 
approach that would need to be considered is the risk of therapy substitution. Many health conditions 
require medical intervention, for which foods cannot substitute. Consumers are attracted to the ready 
availability, economy, and lack of side effects from foods, but must be adequately informed by clear 
labeling when foods cannot substitute for needed medical intervention.  
 
Homeostasis and health: a statistical approach  
 
One sizable challenge due to the current regulatory frameworks is how to conduct meaningful studies on 
probiotics or prebiotics in healthy humans. How does one show that health is improved – or even more 
challenging, maintained - in a healthy person? What does “maintained” mean as a study outcome? One 
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approach is demonstration of reduced incidence of disease or illness. Such a study would be conducted in 
healthy people, but it may be prohibitively expensive due to low incidence or long latency, depending on 
the endpoint being examined. Tracking the incidence of dental caries is an example of an endpoint that 
may be successfully undertaken with a manageable budget and time frame. But measuring the impact on 
immune function with concomitant demonstration of reduced common infectious diseases, for example, 
would be a much more expensive and lengthy study. Another approach, which would not require tracking 
a disease or illness endpoint, would entail measurement of homeostasis, as suggested by D. Tancredi. 
From a statistical point of view, if an intervention were able to minimize the variation around the mean for 
a specific measure (even in the absence of changing the mean; Figure 2), it could be a reflection of 
improved health, assuming a biological rationale exists that tighter control of the parameter is 
physiologically advantageous. In other words, lessening the fluctuation around an individual’s biomarker 
could be interpreted as contributing to improving health. This novel idea emphasizes the importance of 
homeostasis as a focus of studies on health, and provides a rationale based in solid statistical theory as a 
way to measure this.  
 
One challenge to demonstrating the value of this approach is to identify appropriate biomarkers that 
could be studied. The following properties would be important to a biomarker: 
• maintaining moderate levels of the biomarker is associated with good health; 
• high or low values are associated with ill health; 
• biomarker levels in the same person can fluctuate over time; and 
• reducing the magnitude or duration of such fluctuations in healthy people is considered desirable 
(Figure 3). 
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Such a biomarker could be an individual endpoint or be formed as a ratio of two other biomarkers, when 
maintaining the same relative amounts of the two component biomarkers would be desirable. 
 
Assuming a biomarker with the above properties is available, it could be used as the outcome measure in 
a randomized controlled trial to provide evidence that the experimental food is able to improve the 
maintenance of health in humans. Statistically, the trial would be set up to address the hypothesis that the 
experimental substance is associated with lower variation in biomarker levels, compared to the control 
arm, in subjects who were healthy at baseline. Such a trial would be able to use information on within-
person variations in biomarker levels, even those who did not become ill. Partly as a result of the more 
efficient use of study data, such a trial would require far fewer subjects than an intervention that instead 
addressed the hypothesis that treatment is associated with fewer healthy persons becoming ill.  
 
A mounting understanding of the value of stability of the colonizing microbial communities makes this 
endpoint an attractive one to consider. Perturbation of gut microbiota is associated with intestinal 
dysfunction, as illustrated during antibiotic treatment. Specific probiotics have been shown to promote a 
quicker rebound from antibiotic-induced microbiota disruption, including a study on Lactobacillus 
rhamnosus GG (LGG).
21
 This paper concludes “…that a key mechanism for the protective effect of LGG 
supplementation on the subsequent development of allergic disease is through the promotion of a stable, 
even, and functionally redundant infant gastrointestinal community.”  
 
However, it would be useful to define additional biomarkers that would be appropriate targets for this 
type of investigation. 
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In pediatric nutrition, the measurement of metabolic homeostasis has become a standard approach when 
developing infant formulas.
22
 The concept of homeostatis as a model to distinguish between foods (including 
food supplements) and medicinal products was explored by the Council of Europe,
23
 and is an interesting 
correlate to the above hypothesis. 
 
Economic impact 
 
According to a 2006 World Bank report on health enhancing foods, "cost-effectiveness of functional foods 
in reducing disease burden and lost productivity is an important research gap."
24
 While there is a growing 
interest in evidence-based health care, evidence on cost-effectiveness is often lacking. The pharmaceutical 
industry and the medical community have introduced science-based economic evaluation of health 
management programs and care protocols as well as standardized treatment protocols. These studies 
have established the principles of cost-benefit and cost-effectiveness assessments, evaluating not only the 
health spending but also the economic benefits.
25,26
 Such benefits could include, for example, the public 
health savings induced by health management programs. Approaches that establish procedures for the 
assessment of the role of food with particular beneficial effects on health, well-being and quality of life in 
our society are needed. Such assessment would provide important perspective on the economic impact of 
a regulatory framework that encourages research and communication on the health benefits of foods, and 
the subsequent broad implementation in the diet of target populations.  
 
Conclusions 
 
A reassessment of the regulatory approach to functional foods in general, and probiotics and prebiotics in 
particular, is needed. Promulgated in the interest in protecting the consumer from fraudulent claims or 
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from unsafe products, in some cases the regulatory standards being implemented have the unintended 
consequences of keeping valuable information from being communicated to consumers and healthcare 
providers, and perhaps more worrisome, may effectively discourage investment by food companies in 
research to explore the health benefits of their products. Success with research is never guaranteed, but 
companies seek clarity on a research path that at least should have the potential to result in a favorable 
assessment by regulators. Harmonization of different approaches globally would simplify requirements for 
industry, decrease consumer confusion and improve the scientific framework for the research community 
to set up appropriate research pathways. Conversations among all stakeholders to work toward regulatory 
frameworks more consistent with accepted scientific concepts of “continuum” and “suboptimal” are 
needed. The “continuum” approach does not seem fully possible without a change in law, as the current 
law clearly separates products, health conditions and evidence into discrete entities. A more flexible 
approach could contribute to better informed choices, increased consumer protection, and 
encouragement of scientific innovation leading to improved health of the targeted populations. In 
addition, there are few endpoints for human studies that will satisfy the restrictive nature of endpoints 
that are physiologically meaningful but allowable in the current regulatory environment for probiotics and 
prebiotics. Development of new approaches for measuring health, such as the proposed assessment of 
homeostasis, is needed. 
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Table 1. Composition of discussion group convened on the topic of “Health Claims Substantiation for 
Probiotic and Prebiotic Products” at the 8th annual ISAPP meeting. 
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Reg Fletcher Kellogg Europe Trading Ltd IRELAND 
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IPLA (Spanish Government Research Institute) SPAIN 
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James Heimbach JHEIMBACH LLC USA 
Ulrika Hinkel Boehringer Ingelheim GmbH GERMANY 
Ivana Jankovic Nestle SWITZERLAND 
Gunhild Kozianowski Beneo Institute GERMANY 
Jha Ashok Kumar  Sathguru Management Consultants INDIA 
Anu Lähteenmäki-Uutela University of Turku FINLAND 
Niklas Larsson Probi SWEDEN 
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Dundee 
SCOTLAND 
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Lorenzo Morelli Microbiology Institute, Catholic University, Piacenza ITALY 
Raymond O’Rourke Food Lawyer 
 
IRELAND 
Andreu Palou  Spanish Food Agency Authority SPAIN 
Kayla Polzin Cargill USA 
Bruno Pot Institut Pasteur de Lille FRANCE 
Ger Rijkers Department of Medical Microbiology and Immunology, 
St. Antonius Hospital, Nieuwegein  
NETHERLANDS 
Yolanda Sanz Institute of Agrochemistry and Food Technology, 
Spanish National Research Council 
SPAIN 
Margriet Schoterman FrieslandCampina Domo NETHERLANDS 
Dan Tancredi Assistant Professor of Pediatrics,  
UC Davis School of Medicine and Center for Healthcare 
Policy and Research 
USA 
Henk van Loveren Professor of Immunotoxicology, Maastricht University NETHERLANDS 
Carey Walker Mead Johnson Nutrition USA 
Rob Welch University of Ulster Coleraine NORTHERN IRELAND 
Jia Zhao Yakult Europe NETHERLANDS 
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Table 2. Outline for discussion on the topic of “Health Claims Substantiation for Probiotic and Prebiotic 
Products” at the 8th annual ISAPP meeting. 
 
Brief update on current situation with claims on probiotic/prebiotic products 
Standards of evidence required for claims: 
• How much is enough 
• What types are enough 
• Is scientific rigor and magnitude of effects required for foods/supplements the same as for drugs? 
• What is a "gold standard" of evidence for probiotic foods/supplements? 
Overview of the challenges of nutrition research: establishing causality between foods and health benefits 
Perspectives of a biostatistician on: 
• Negative studies or conflicting results  
• Statistical significance compared to biological meaningfulness 
• The lack of the ideal human trial 
What study populations are appropriate for food claims? 
• Extrapolation from study populations to general population 
• Population subgroups: elderly, infants, children, etc. 
• How might approaches need to adapt with new information from human microbiome project, 
individualized nutrition issues? 
Guidelines for the design, conduct and reporting of human studies to evaluate the health benefits of foods  
Wording of health claims 
Probiotic/prebiotic research targets often are on endpoints that are not measurable with validated 
biomarkers and have no recognized risk factors that are intermediate measures of health responses. What 
are recommendations for research on probiotics/prebiotics for foods? 
Clinical endpoints and biomarkers in probiotic research 
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• Present proposal to develop a position paper on biomarkers/ risk factors with the following goals: 
o analyze all the markers used to assess health benefits in human studies with pro and prebiotics 
(we can start with ILSI guidelines and list all markers and benefits mentioned there) 
o estimate the relevance of using biomarkers compared to clinical outcomes and propose the 
best solution for each benefit 
o analyze each of the proposed biomarkers (method of assessment, levels in healthy individuals, 
increased risk levels, validation status…) drawing from available literature 
o propose what needs to be done to validate each biomarker 
• Present example biomarkers (validated and non-validated)  
• Is there consensus of value of proceeding with this? If so, than how to do it (ISAPP, ILSI, both or ?) 
Perspectives on the problem of bioequivalency among different in vitro factors that might impact probiotic 
functionality in vivo 
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Figure 1. Regulatory compared to scientific understanding of terms found in food and drug law. In 
regulations, discrete distinctions are made between health and disease, food and drugs and acceptable 
and unacceptable levels of evidence to support claims. In scientific practice, these concepts are 
understood to span a continuum. 
 
 
 
 
 
 
  
 
 
 
Figure 2. Visualization of the concept of improved homeostasis. An intervention able to minimize the 
variation around the mean for a specific measure, even in the absence of changing 
demonstration of improved homeostasis. 
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the mean, would be a 
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Figure 3. The concept of homeostasis, as expressed by reducing the magnitude or duration of fluctuations. 
Such a study could be conducted in healthy people, by collecting repeated measures of the physiological 
measure and comparing intervention and control groups on summary measures of the amount of within-
person fluctuation. The study design could also include a timed sequence of challenges designed to 
disturb the measure, allowing between-group comparisons on resistance to perturbation. Modified after 
Ger Rijkers, personal communication. 
 
 
